| Title |
Bevacizumab in the treatment of ovarian cancer
|
|---|---|
| Published in |
Biologics: Targets & Therapy, January 2011
|
| DOI | 10.2147/btt.s13071 |
| Pubmed ID | |
| Authors |
Ramez N Eskander, Leslie M Randall |
| Abstract |
Despite advances in surgical cytoreduction and cytotoxic chemotherapy, ovarian cancer continues to be the leading cause of death in women with gynecologic malignancy. Our understanding of the treatment of ovarian cancer was revolutionized with the discovery of platinum- and taxane-based adjuvant chemotherapy regimens. Since that time however, overall survival has been stable. Given the above, an emphasis has been placed on exploring alternative therapeutics. Recent research efforts have improved our understanding of the molecular biology of ovarian cancer and novel targeted treatment strategies have emerged. The most studied of these agents has been the monoclonal anti-vascular endothelial growth factor antibody bevacizumab. The purpose of this review is to discuss management issues related to the treatment of ovarian cancer, with a focus on the utilization of bevacizumab, summarizing applicable clinical trials, its potential benefits, and reported adverse events. |
Mendeley readers
The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 33 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 18% |
| Student > Master | 6 | 18% |
| Other | 4 | 12% |
| Researcher | 4 | 12% |
| Student > Ph. D. Student | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 8 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 36% |
| Agricultural and Biological Sciences | 5 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Business, Management and Accounting | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 10 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 March 2020.
All research outputs
#5,461,184
of 25,806,080 outputs
Outputs from Biologics: Targets & Therapy
#71
of 286 outputs
Outputs of similar age
#33,790
of 192,774 outputs
Outputs of similar age from Biologics: Targets & Therapy
#2
of 5 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 286 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,774 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.